Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Centralna Biblioteka Wojskowa Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaCentralna Biblioteka Wojskowa

Wyszukujesz frazę "Multiple myeloma" wg kryterium: Temat

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-7 z 7
    Tytuł:
    The massive nodular cutaneous and soft tissues lesions of the right shoulder and the arm as the extramedullary manifestation of the advanced stage of multiple myeloma
    Autorzy:
    Drobiecki, Arkadiusz
    Pasiarski, Marcin
    Stelmach-Gołdyś, Agnieszka
    Garus, Bartosz
    Powiązania:
    https://bibliotekanauki.pl/articles/773404.pdf
    Data publikacji:
    2017
    Wydawca:
    Medical Education
    Tematy:
    cutaneous involvement
    multiple myeloma
    Opis:
    Cutaneous and soft tissue involvement is a very rare manifestation of multiple myeloma. We are describing a woman with the huge multiple plasma cells infiltrations of the soft tissues and the skin of the right shoulder and the arm that had occurred 2.5 years after the diagnosis of multiple myeloma. In the case of the described patient there is a distinct correlation between the appearance of the nodular lesions in soft tissues and the underlying osteolytic changes found in the skeleton. We assumed that the fracture of the right humerus in the past was the beginning of the plasma cells dissemination in the adherent tissues. The skin changes in our patient appeared in the advanced stage of multiple myeloma. There was only transient improvement of cutaneous changes after the chemotherapy, despite the complete remission of the underlying disease in the bone marrow. Despite of the intensive treatment (chemotherapy, radiotherapy) the patient died 7 months after the first appearance of the skin changes.
    Źródło:
    OncoReview; 2017, 7, 4; 180-183
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Multiple myeloma – cancer among elderly people
    Autorzy:
    Januszewska, Joanna
    Świderska-Kołacz, Grażyna
    Zmorzyński, Szymon
    Powiązania:
    https://bibliotekanauki.pl/articles/472516.pdf
    Data publikacji:
    2016
    Wydawca:
    Uniwersytet Pedagogiczny im. Komisji Edukacji Narodowej w Krakowie
    Tematy:
    multiple myeloma
    etiology of multiple myeloma
    epidemiology
    prognostic factors
    genetic mutations
    chromosomal abberration
    Źródło:
    Annales Universitatis Paedagogicae Cracoviensis. Studia ad Didacticam Biologiae Pertinentia; 2016, VI; 52-61
    2083-7267
    2450-3487
    Pojawia się w:
    Annales Universitatis Paedagogicae Cracoviensis. Studia ad Didacticam Biologiae Pertinentia
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    IgM multiple myeloma: diagnostic difficulties and results of bortezomib treatment – case report
    Autorzy:
    Machowicz, Rafał
    Skwierawska, Kamila
    Mądry, Krzysztof
    Górka, Michał
    Żurawska, Jagoda
    Kacprzyk, Piotr
    Waszczuk-Gajda, Anna
    Dwilewicz-Trojaczek, Jadwiga
    Powiązania:
    https://bibliotekanauki.pl/articles/773502.pdf
    Data publikacji:
    2014
    Wydawca:
    Medical Education
    Tematy:
    IgM
    Waldenström’s macroglobulinemia
    bortezomib
    multiple myeloma
    Opis:
    The IgM paraprotein secretion is most frequently associated with Waldenström’s macroglobulinemia. In very rare cases it may also occur in multiple myeloma. The diagnostic and therapeutic process of a 84 year old male suffering from IgM multiple myeloma is described, including difficulties in establishing this diagnosis. Due to infectious complications, after the first cycle of melphalan– prednisone–bortezomib treatment, melphalan was stopped, subsequently, bortezomib and prednisone doses were also reduced. Two treatment interruptions have occurred. Despite reduced treatment intensity, the patient was in very good partial remission, while the toxicity profile was acceptable. IgM multiple myeloma should be included in the differential diagnosis of IgM paraproteinemia, also when osteolytic lesions and translocation 11:14 are not detected. Bortezomib-based therapy can be effective in elderly patients (also in those suffering from cardiac insufficiency), even when dose reduction is required.
    Źródło:
    OncoReview; 2014, 4, 4; A160-A164
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Targeting the hypoxia pathway in malignant plasma cells by using 17-allylamino-17-demethoxygeldanamycin
    Autorzy:
    Kocemba-Pilarczyk, Kinga
    Ostrowska, Barbara
    Trojan, Sonia
    Aslan, Ecce
    Kusior, Dorota
    Lasota, Małgorzata
    Lenouvel, Claire
    Dulińska-Litewka, Joanna
    Powiązania:
    https://bibliotekanauki.pl/articles/1038530.pdf
    Data publikacji:
    2018
    Wydawca:
    Polskie Towarzystwo Biochemiczne
    Tematy:
    Multiple myeloma
    HIF-1
    hypoxia
    17-AAG
    Opis:
    Multiple myeloma (MM) is characterized as a clonal expansion of malignant plasma cells in the bone marrow, which is often associated with pancytopenia and osteolytic bone disease. Interestingly, myeloma-infiltrated bone marrow is considered to be hypoxic, providing selection pressure for a developing tumour. Since HSP90 was shown to participate in stabilization of the subunit of the key transcription factor HIF-1, which controls the hypoxic response, the aim of this study was to investigate the influence of a HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG), on MM cells cultured under low oxygenation conditions. We confirmed that 17-AAG inhibits hypoxic induction of the HIF-1 target genes in malignant plasma cells and demonstrate the concentration range of severe hypoxia-specific cytotoxicity. Next, we selected the malignant plasma cells under severe hypoxia/re-oxygenation culture conditions in the presence or absence of 17-AAG and subsequently, the cells which survived were further expanded and analyzed. Interestingly, we have noticed significant changes in the survival and the response to anti-MM drugs between the parental cell lines and those selected in cyclic severe hypoxia in the presence and absence of 17-AAG. Importantly, we also observed that the lack of oxygen itself, irrespectively of HIF-1 inhibition, is the main/pivotal factor driving the selection process in the experiments presented here.
    Źródło:
    Acta Biochimica Polonica; 2018, 65, 1; 101-109
    0001-527X
    Pojawia się w:
    Acta Biochimica Polonica
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    The efficacy of combination therapy with lenalidomide and dexamethasone in the treatment of relapsed multiple myeloma
    Autorzy:
    Szudy-Szczyrek, A.
    Legiec, W.
    Mańko, J.
    Gmyz, K.
    Szczyrek, M.
    Hus, M.
    Powiązania:
    https://bibliotekanauki.pl/articles/2052439.pdf
    Data publikacji:
    2015
    Wydawca:
    Akademia Bialska Nauk Stosowanych im. Jana Pawła II w Białej Podlaskiej
    Tematy:
    multiple myeloma
    immunomodulatory drugs
    maintenance therapy
    lenalidomide
    Opis:
    Multiple myeloma is a neoplastic disease which is characterised by proliferation of monoclonal plasmocytes in the bone marrow. It is the second most common hematologic cancer and it represents 1% of all cancer deaths. Despite enormous development in multiple myeloma biology and treatment over the last 30 years - it is still incurable disease with a median survival of 50 – 55 months. Currently, one of the most important goals in the treatment of multiple myeloma is to achieve long-term control of the disease, without negative impact on the patient’s quality of life. Thanks to therapeutic regimens based on new immunomodulatory drugs, this aim seems to be achievable. In this paper we present the case of a female patient living with multiple myeloma for 14 years. Initially patient was treated with standard VAD (vincristine, doxorubicin, dexamethasone) chemotherapy regimen. After a nearly complete remission of the disease, autotransplantation of hematopoietic cells was performed. One year after transplantation there was a relapse of the disease. In the treatment of relapse it was decided to use scheme based on lenalidomide and dexamethasone. After 4th cycle of treatment, a complete remission was achieved. So far, the patient received 149 cycles. In the evaluation of minimal residual disease still maintains a state of complete remission maintains. During over 12 years of treatment no complications in grade 3 and 4 of the CTCAE v.4 was observed. Currently the patient is 58 years old, she still receives lenalidomide and leads moderately active life.
    Źródło:
    Health Problems of Civilization; 2015, 09, 2; 50-54
    2353-6942
    2354-0265
    Pojawia się w:
    Health Problems of Civilization
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Poziom depresji a pojawianie się zmian poznawczych u chorych na szpiczaka mnogiego - doniesienia wstępne
    Level of depression and occurrence of cognitive changes in patients with multiple myeloma - a preliminary report
    Autorzy:
    Bury-Kamińska, Magdalena
    Szudy-Sczyrek, Aneta
    Kozłowiec, Monika
    Jankowska-Łęcka, Olga
    Nowaczyńska, Aleksandra
    Hus, Marek
    Powiązania:
    https://bibliotekanauki.pl/articles/2096946.pdf
    Data publikacji:
    2022-07-31
    Wydawca:
    Wyższa Szkoła Gospodarki Euroregionalnej im. Alcide De Gasperi w Józefowie
    Tematy:
    depression
    chemobrain
    multiple myeloma
    cancer
    cognitive dysfunctions
    depresja
    szpiczak plazmocytowy
    nowotwór
    zaburzenia poznawcze
    Opis:
    The aim of the article is to study the changes in the level of cognitive and affective functioning in patients with multiple myeloma undergoing chemotherapy. Montreal Cognitive Assessment scale (MoCA) – screening method – was used to determine the general cognitive state of patients. The general level of depression and its characteristic symptoms were determined with the use of Depression Measurement Questionnaire. Gathering first initial results of author’s own research – increasing the research sample could indicate an improved cognitive functioning in patients with multiple myeloma during chemotherapeutic treatment. Moreover, the research demonstrates a decrease in depression symptoms, i.e., self-blame and anxiety states, during chemotherapy. The study requires further research owing to a small group of research participants (n = 21), the presence of research data at the level of statistical tendency, and a need for a comparison with a group of healthy people (without a cancer diagnosis).
    Celem artykułu jest zbadanie zmian w poziomie funkcjonowania poznawczego i afektywnego u pacjentów chorych na szpiczaka mnogiego przechodzących chemoterapię. Do określenia ogólnego stanu poznawczego pacjentów użyto Montrealskiej Skali Oceny Funkcji Poznawczych – metody przesiewowej. Ogólny poziom depresji oraz charakterystyczne objawy tego zaburzenia zostały określone na podstawie narzędzia – Kwestionariusza do Pomiaru Depresji. Uzyskano pierwsze wstępne wyniki badań własnych, które przy zwiększeniu próby badawczej mogłyby świadczyć lepszym funkcjonowaniu poznawczym pacjentów chorych na szpiczaka mnogiego w trakcie leczenia chemioterapeutycznego. Ponadto odnotowano spadek objawów depresji, tj. poczucia winy i napięcia lękowego podczas terapii onkologicznej. Badania wymagają kontynuacji, ze względu na nieliczną grupę osób badanych (n = 21), wyniki na poziomie tendencji statystycznej oraz chęć porównania rezultatów badanych z grupą osób zdrowych (bez diagnozy nowotworu).
    Źródło:
    Journal of Modern Science; 2022, 48, 1; 461-475
    1734-2031
    Pojawia się w:
    Journal of Modern Science
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Ocena przydatności oznaczania w surowicy krwi stężenia wolnych łańcuchów lekkich immunoglobulin w diagnostyce chorych z dyskrazjami plazmocytowymi*
    The usefulness of evaluating serum immunoglobulin light free chains concentration in diagnosis of patients with plasma cell disorder
    Autorzy:
    Gumółka, Izabela
    Dryńska-Lichoń, Ewa
    Basa, Joanna
    Powiązania:
    https://bibliotekanauki.pl/articles/1034994.pdf
    Data publikacji:
    2013
    Wydawca:
    Śląski Uniwersytet Medyczny w Katowicach
    Tematy:
    slfc (serum light free chain)
    mm (multiple myeloma)
    smm (smouldering myeloma)
    mgus (monoclonal
    gammopathy of undetermined significance)
    cll (non-hodgkin lymphoma)
    al (amyloidosis)
    lcmm (light
    chain myeloma)
    Opis:
    Patients with plasma cell disorder require a medical examination that will enable in a quick way to make a diagnosis, treatment selection and conduct patient monitoring during drug therapy. The aim of this study was to determine the concentration of serum immunoglobulin and light free chains in patients with monoclonal gammopathy. The blood serum of patients was evaluated in the Beskid Hematological Clinic Cancer Center – City Hospital in Bielsko-Biała. The serum of immunoglobulin light free chains was determined by using commercially available tests by the Binding Site company. Assay validation was performed in the serum light free chains of immunoglobulin by setting the analytical range of the method, linearity, precision, analytical sensitivity, recurrence and limit of detection as well as quantification methods. The results obtained indicate that the determination of serum immunoglobulin and light free chains is important in the diagnosis of patients with multiple myeloma and other monoclonal gammopathy, such as smouldering myeloma, light chain disease, gammopathy of undetermined significance, non-Hodgkin lymphoma and amyloidosis.
    Źródło:
    Annales Academiae Medicae Silesiensis; 2013, 67, 4; 249-255
    1734-025X
    Pojawia się w:
    Annales Academiae Medicae Silesiensis
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
      Wyświetlanie 1-7 z 7

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies